CliffBio
small molecule

XADAGO

SAFINAMIDE MESYLATE

Loss of exclusivityMarch 2031latest FDA-listed patent expiry
CompanyMDD US OPERATIONS, LLC →View the full company profile on CliffBio

Drug detail

Brand nameXADAGO
Active ingredientSAFINAMIDE MESYLATE
StrengthEQ 50MG BASE
Dosage formTABLET
RouteORAL
ModalitySmall molecule
FDA approvalMarch 2017
Marketing statusRX

Listed patents

PatentExpiresType
8283380March 2031use U-1993
8076515December 2028substance, product
8278485June 2027substance

More from MDD US OPERATIONS, LLC

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.

XADAGO patent cliff — loss of exclusivity March 2031 | CliffBio